RYAM Q1 Results In Line, But Turnaround Hurdles Persist

What happened

RYAM's Q1 2026 results matched the trajectory laid out in March, with early wins in Cellulose Specialties pricing and mix and positive adjusted free cash flow. However, adjusted free cash flow was generated from a low earnings base, and GAAP losses continued. The company still faces a heavy debt load of ~$794M, interest coverage of just 0.05x, and a 2025 EBITDA guide that is well below 2024 levels. Management's longer-term target of >$300M EBITDA by 2027 remains highly aspirational given the cyclical and competitive pressures in pulp and paper. Execution on cost cuts and biomaterials projects will be critical, but the balance sheet leaves little room for error.

Implication

The quarter shows RYAM is on track operationally, but financial leverage and low GAAP earnings mean the equity is still speculative. Investors should require evidence of sustained positive free cash flow over $50-75M and leverage trending below 3x before adding exposure. The gap between DCF value and market price reflects skepticism that management's ambitious 2027 targets are achievable.

Thesis delta

The thesis remains WAIT. Q1 results do not materially change the risk-reward profile. The positive adjusted FCF is encouraging but not sufficient to upgrade the stance given the weak interest coverage and high debt. Further evidence of deleveraging and consistent FCF generation is needed to consider a shift.